Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019–2020: A Test-Negative Study
Author(s) -
Carlos G. Grijalva,
Leora R. Feldstein,
H. Keipp Talbot,
Michael S. Aboodi,
Adrienne Baughman,
Samuel M. Brown,
Jonathan D. Casey,
Heidi L. Erickson,
Matthew C. Exline,
D. Clark Files,
Kevin W. Gibbs,
Adit A. Ginde,
Michelle N. Gong,
Natasha Halasa,
Akram Khan,
Christopher J. Lindsell,
Samuel Nwosu,
Ithan D. Peltan,
Matthew E. Prekker,
Todd W. Rice,
Nathan I. Shapiro,
Jay S. Steingrub,
William B. Stubblefield,
Mark W. Tenforde,
Manish M. Patel,
Wesley H. Self
Publication year - 2021
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab462
Subject(s) - medicine , influenza vaccine , influenza like illness , test (biology) , immunology , vaccination , virology , intensive care medicine , virus , paleontology , biology
Influenza vaccine effectiveness (VE) against a spectrum of severe disease, including critical illness and death, remains poorly characterized.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom